年销售额（USD）
100,000,000至249,999,999
企业简介
四川宏明博思药业有限公司成立于2013年，专注于原料药和制剂的生产。现有员工400余人，主要生产高端剂型如注射剂、冻干粉针剂、片剂和胶囊剂。宏明博思的冻干粉针制剂生产线已获得EU GMP，并通过巴西ANVISA现场检查。目前四川宏明博思冻干粉针制剂的多个产品在巴西、智利、秘鲁、危地马拉、泰国、菲律宾、马来西亚、南非、澳大利亚等开展注册中。Sichuan Omnis Pharmaceutical Co., Ltd. was established in 2013, focusing on the manufacture of FDFs and APIs, located in Sichuan Chengdu, China. It currently has more than 400 employees and mainly produces high-end dosage forms such as injections, lyophilized powder injections, tablets and capsules. Omnis has granted China/EU/ANVISA/PICs GMP for lyophilized powder injection line. Currently, multiple products of lyophilized powder injection are undergoing registration in Brazil, Chile, Peru, Guatemala, Thailand, the Philippines, Malaysia, South Africa, Australia, and other countries.
主要竞争优势
品牌,国际认证/标准,经验丰富的研发人员,发货速度,生产能力,产品线丰富,合同定制（CRO,CMO）,接受买家的规格要求,接受小额订单,良好的信誉,优质服务
里程碑
2013年1月，成都百裕金阁莱药业有限公司成立Jan. 2013, Established Chengdu Baiyu Ginkgolide Pharmaceutical Co., Ltd2013年12月，开工奠基Dec. 2013, Groundbreaking 2018年3月，启动商业化生产Mar. 2018, Launched commercial production2018年4月，与ELC医药签署欧盟2个产品商务合同Apr. 2018, Signed commercial contract with ELC Pharmaceutical for2 products in EU 2022年3月，通过欧盟认证现场检查Mar. 2022, Passed the EU GMP certification on-site inspection2022年8月，百裕金阁莱更名为四川宏明博思药业有限公司Aug. 2022, Baiyu Ginkgolide changed its name to Sichuan Omnis Pharmaceutical Co. Ltd2022年12月，四川生物医药集团与百裕制药签订战略协议Dec. 2022, Biomedical Industrial Group signed a strategic agreement with Baiyu Pharmaceuticals 2023年1月-2月，取得宏明博思药品生产许可证产品批件、GMP认证Jan.-Feb. 2023, Obtained the DML, product certificate, China GMP2023年5月，取得欧盟认证证书通过巴西认证现场审计检查May 2023, Granted the EU GMP and passed the on-site audit inspection by ANVISA2023年7月，取得ANVISA GMPJul. 2023, Granted the ANVISA GMP
